Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23225325 | 0.97 | S1PR5 (0.34) | S1PR5S1PR4HSD17B1HSD17B2CA12 | |
| SCHEMBL24919218 | 0.97 | S1PR5 (0.37) | S1PR5S1PR4HSD17B1HSD17B2ALOX5 | |
| SCHEMBL24472162 | 0.96 | S1PR5 (0.35) | S1PR5S1PR4ALOX5CA12CA1 | |
| SCHEMBL24471998 | 0.95 | S1PR5 (0.34) | S1PR5S1PR4 | |
| SCHEMBL25536425 | 0.94 | S1PR5 (0.35) | S1PR5S1PR4HSD17B1HSD17B2ALOX5 | |
| SCHEMBL24472397 | 0.93 | S1PR5 (0.34) | S1PR5S1PR4 | |
| SCHEMBL24472530 | 0.93 | S1PR5 (0.34) | S1PR5S1PR4 | |
| SCHEMBL25533894 | 0.93 | S1PR5 (0.38) | S1PR5S1PR4ALOX5GSTP1 | |
| SCHEMBL25534051 | 0.93 | S1PR5 (0.38) | S1PR5S1PR4ALOX5GSTP1 | |
| SCHEMBL25137804 | 0.93 | S1PR5 (0.36) | S1PR5S1PR4HSD17B1HSD17B2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172058-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230172058-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172058-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | LEF1, PIEZO1, ELAVL1 | S1PR5 4533/4885S1PR4 3989/4885HSD17B1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.